【摘要】 目的 :检测 p5 3、C- erb B- 2与 PCNA的异常表达可能为区别不同组织良、恶性病变提供可靠客观的指标。 方法 :对 6 6 3例恶性肿瘤 (包括鳞癌、腺癌、黑色素瘤 )及 5 6 6例良性病变 (包括乳头状瘤、腺瘤及慢性炎病变 )组织 p5 3、C- erb B- 2及 PCNA表达进行免疫组化检测。结果:恶性肿瘤 p5 3、C- erb B- 2及 PCNA表达阳性的检出率分别为 6 2 .7%、85 .8%及 94.7% ,明显较良性肿瘤与炎性病变为高 (分别为 0～ 11% ,12 .8%～ 45 .5 %及 13.6 %～6 1.8% ) (P <0 .0 5～ 0 .0 0 1)。结论:抑癌基因 p5 3的突变、癌基因 C- erb B- 2的过度表达与扩增及 PCNA的过高表达是恶性病变的共同特征 ,可以作为诊断或区别诊断良恶性病变的重要分子标志。更多还原

【Abstract】 Objective: Detection of p53?C-erbB-2?PCNA alterated expression may offer important index for diagnosis of benign and malignant human lesions. Methods: p53?C-erbB-2 and PCNA exprssions in 663 malignant (squmeous cell carcinoma, adenocarcinoma, melanoma) and 566 benign (adenoma?papilloma and chronic inflammatory) lesions were detected by immunohistochemistry (LSAB). Results: Overexpression of p53?C-erbB-2 and PCNA in malignant lesions was 62.7%, 85.8%, and 94.7% revealing significantly higher than in benign lesions (0~11%, 12.8~45.5%, and 13.6~61.8%) (P<0.05~0.001) respectively. Conclusion: Mutation of tumor suppressor gene p53, overexpression and amplification of oncogenes in human malignant lesions may be an important biomolecular marker for diagnosis or differential dignosis on both benign and malignant lesions.更多还原